You searched for "registrar"
Sexually transmitted conjunctivitis – the REALLY sticky eye
Let’s face it, patients with conjunctivitis don’t always produce the most stimulating consultations and most of the time we can manage them in auto-pilot. The prospect of delving into such a patient’s sexual history is not overly appealing, but this...The assessment of pupils and pupillary reactions
Understanding pupillary reactions is vital in understanding basic neuro-opthalmology. It is a skill required in eye casualty, clinics and perhaps most importantly, exams. To start at the beginning, the pupil is the central aperture of the iris, its size controlling...
Tocilizumab in Graves’ orbitopathy
This prospective European study looks at the response to tocilizumab in corticosteroid-resistant disease. Tocilizumab (TCZ) is a monoclonal antibody that competitively inhibits IL-6 binding to its receptor. Unlike teprotumumab, the advantage of TCZ is that it is already used within...Preview: Oxford Ophthalmological Congress
Between 1–3 July, we will be heading down to England for the 107th Oxford Ophthalmological Congress.The curse of the college museum
David Greig lecture notebook. Courtesy of Dr Jacqueline Cahif, College Archivist, Royal College of Surgeons of Edinburgh. As sure as the inevitability of death and taxes, the hidden stories of past events will intermittently rise to the surface like oil...Belfast briefing: Retina Day roundup from the RCOphth 2024 Annual Congress
Belfast hosted this year’s Royal College of Ophthalmologists’ (RCOphth) Annual Congress, a meeting dedicated to sharing advances, knowledge and clinical practice points in ophthalmic care. This article summarises selected talks by medical and surgical retina specialists during the Retina Subspecialty...Preview: UKISCRS 48th Annual Congress 2024
One of the biggest UKISCRS events is upon us, and we’ll all by making our way down there in the next several weeks or so. Not only is it the 75th anniversary of the IOL, but it is also the...
Type 3 CNV and anti-VEGF
The purpose of the study was to determine the differences between aflibercept and ranibizumab in terms of their therapeutic efficacy in the treatment of Type 3 neovascularisation. The authors highlight that the dominant mechanism for Type 3 neovascularisation development is...
